Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis
- PMID: 12714172
- DOI: 10.1016/s0925-4927(02)00118-x
Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis
Abstract
Magnetic resonance imaging (MRI) and positron emission tomography (PET) studies of the frontal and temporal lobes in schizophrenia patients and healthy controls have proliferated over the past 2 decades, but there have been relatively few attempts to quantify the evidence. In this meta-analytic review, 155 studies on frontal and temporal lobe neurobiology were synthesized, reflecting results from 4043 schizophrenia patients and 3977 normal controls. Cohen's d was used to quantify case-control differences, and moderator variable analysis indexed the relation of sample and imaging characteristics to the magnitude of these differences. Frontal metabolic and blood flow deficiencies in conjunction with cognitive activation tasks ("hypofrontality") emerged as the strongest body of evidence, demonstrating abnormalities that distinguish approximately half of schizophrenia patients from healthy people. Most case-control comparisons with structural and functional imaging yield small and in many cases unstable findings. Technical scanning parameters like slice thickness and magnet strength did not vary with case-control differences consistently across the meta-analyses. However, patient sample characteristics including sample size, handedness and gender composition emerged frequently as moderators of brain-imaging effect sizes.
Similar articles
-
The frontal lobes, basal ganglia, and temporal lobes as sites for schizophrenia.Schizophr Bull. 1990;16(3):379-89. doi: 10.1093/schbul/16.3.379. Schizophr Bull. 1990. PMID: 2287929 Review.
-
A computational morphometric MRI study of schizophrenia: effects of hallucinations.Cereb Cortex. 2002 Dec;12(12):1331-41. doi: 10.1093/cercor/12.12.1331. Cereb Cortex. 2002. PMID: 12427683
-
What have we learned from functional imaging studies in schizophrenia? The role of frontal, striatal and temporal areas.Aust N Z J Psychiatry. 1996 Apr;30(2):195-209. doi: 10.3109/00048679609076095. Aust N Z J Psychiatry. 1996. PMID: 8811262 Review.
-
[Hypofrontality and negative symptoms in schizophrenia: synthesis of anatomic and neuropsychological knowledge and ecological perspectives].Encephale. 2001 Sep-Oct;27(5):405-15. Encephale. 2001. PMID: 11760690 Review. French.
-
Hypofrontality in schizophrenia: a review of the evidence.Can J Psychiatry. 1987 Jun;32(5):399-404. doi: 10.1177/070674378703200516. Can J Psychiatry. 1987. PMID: 3308053 Review.
Cited by
-
Altered Patterns of Brain Glucose Metabolism Involve More Extensive and Discrete Cortical Areas in Treatment-resistant Schizophrenia Patients Compared to Responder Patients and Controls: Results From a Head-to-Head 2-[18F]-FDG-PET Study.Schizophr Bull. 2023 Mar 15;49(2):474-485. doi: 10.1093/schbul/sbac147. Schizophr Bull. 2023. PMID: 36268829 Free PMC article.
-
Caffeine-Induced Acute and Delayed Responses in Cerebral Metabolism of Control and Schizophrenia-Like Wisket Rats.Int J Mol Sci. 2022 Jul 25;23(15):8186. doi: 10.3390/ijms23158186. Int J Mol Sci. 2022. PMID: 35897774 Free PMC article.
-
Shape features of working memory-related deep-brain regions differentiate high and low community functioning in schizophrenia.Schizophr Res Cogn. 2022 Mar 29;29:100250. doi: 10.1016/j.scog.2022.100250. eCollection 2022 Sep. Schizophr Res Cogn. 2022. PMID: 35368990 Free PMC article.
-
Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia.CNS Drugs. 2022 Jan;36(1):1-16. doi: 10.1007/s40263-021-00884-z. Epub 2021 Dec 20. CNS Drugs. 2022. PMID: 34928485 Review.
-
Anger Experience and Anger Expression Through Drawing in Schizophrenia: An fNIRS Study.Front Psychol. 2021 Sep 1;12:721148. doi: 10.3389/fpsyg.2021.721148. eCollection 2021. Front Psychol. 2021. PMID: 34539522 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous